Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
申请人:Chao J. Hannguang
公开号:US20050267119A1
公开(公告)日:2005-12-01
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
申请人:Chao Hannguang J.
公开号:US20080280905A1
公开(公告)日:2008-11-13
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS
申请人:Herpin Timothy F.
公开号:US20080275090A1
公开(公告)日:2008-11-06
The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
Amino-benzazoles as P2Y1 receptor inhibitors with pyridine ring and heterocyclic components
申请人:Bristol-Myers Squibb Company
公开号:US08053450B2
公开(公告)日:2011-11-08
The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.